85 related articles for article (PubMed ID: 24763037)
1. [CAL-101,a novel agent of targeted therapy in hematological malignancies].
Li CJ; Zhang Q; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):530-3. PubMed ID: 24763037
[TBL] [Abstract][Full Text] [Related]
2. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
Hoellenriegel J; Meadows SA; Sivina M; Wierda WG; Kantarjian H; Keating MJ; Giese N; O'Brien S; Yu A; Miller LL; Lannutti BJ; Burger JA
Blood; 2011 Sep; 118(13):3603-12. PubMed ID: 21803855
[TBL] [Abstract][Full Text] [Related]
3. Combining CAL-101 with Celecoxib Enhances Apoptosis of EBV-transformed B-Cells Through MAPK-induced ER Stress.
Park GB; Hur DY; Kim D
Anticancer Res; 2015 May; 35(5):2699-708. PubMed ID: 25964548
[TBL] [Abstract][Full Text] [Related]
4. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.
Lannutti BJ; Meadows SA; Herman SE; Kashishian A; Steiner B; Johnson AJ; Byrd JC; Tyner JW; Loriaux MM; Deininger M; Druker BJ; Puri KD; Ulrich RG; Giese NA
Blood; 2011 Jan; 117(2):591-4. PubMed ID: 20959606
[TBL] [Abstract][Full Text] [Related]
5. PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic.
Fruman DA; Rommel C
Cancer Discov; 2011 Dec; 1(7):562-72. PubMed ID: 22586681
[TBL] [Abstract][Full Text] [Related]
6. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.
Herman SE; Gordon AL; Wagner AJ; Heerema NA; Zhao W; Flynn JM; Jones J; Andritsos L; Puri KD; Lannutti BJ; Giese NA; Zhang X; Wei L; Byrd JC; Johnson AJ
Blood; 2010 Sep; 116(12):2078-88. PubMed ID: 20522708
[TBL] [Abstract][Full Text] [Related]
7. Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia.
Herman SE; Johnson AJ
Clin Cancer Res; 2012 Aug; 18(15):4013-8. PubMed ID: 22711705
[TBL] [Abstract][Full Text] [Related]
8. Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.
Davies A
Expert Rev Hematol; 2015 Oct; 8(5):581-93. PubMed ID: 26343890
[TBL] [Abstract][Full Text] [Related]
9. Management of adverse events associated with idelalisib treatment: expert panel opinion.
Coutré SE; Barrientos JC; Brown JR; de Vos S; Furman RR; Keating MJ; Li D; O'Brien SM; Pagel JM; Poleski MH; Sharman JP; Yao NS; Zelenetz AD
Leuk Lymphoma; 2015; 56(10):2779-86. PubMed ID: 25726955
[TBL] [Abstract][Full Text] [Related]
10. PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.
Wang X; Ding J; Meng LH
Acta Pharmacol Sin; 2015 Oct; 36(10):1170-6. PubMed ID: 26364801
[TBL] [Abstract][Full Text] [Related]
11. Idelalisib for chronic lymphocytic leukemia.
Brown JR
Clin Adv Hematol Oncol; 2014 Dec; 12(12):846-8. PubMed ID: 25674842
[No Abstract] [Full Text] [Related]
12. CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies.
Castillo JJ; Furman M; Winer ES
Expert Opin Investig Drugs; 2012 Jan; 21(1):15-22. PubMed ID: 22112004
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic modeling of idelalisib, a novel PI3Kδ inhibitor, in healthy subjects and patients with hematologic malignancies.
Jin F; Gao Y; Zhou H; Fang L; Li X; Ramanathan S
Cancer Chemother Pharmacol; 2016 Jan; 77(1):89-98. PubMed ID: 26645408
[TBL] [Abstract][Full Text] [Related]
14. More on Merkel-Cell Carcinoma.
Blom A; Saiag P
N Engl J Med; 2016 Feb; 374(5):494-5. PubMed ID: 26840149
[No Abstract] [Full Text] [Related]
15. More on Merkel-Cell Carcinoma.
Shiver MB; Mahmoud F; Gao L
N Engl J Med; 2016 Feb; 374(5):495. PubMed ID: 26840148
[No Abstract] [Full Text] [Related]
16. NCCN Awarded $2 Million in Research Funding from Infinity Pharmaceuticals to Study Duvelisib in Hematologic Malignancies.
J Natl Compr Canc Netw; 2016 Mar; 14(3):xl. PubMed ID: 27396030
[No Abstract] [Full Text] [Related]
17. Idelalisib for the treatment of indolent non-Hodgkin's lymphoma.
Lopez JP; Jimeno A
Drugs Today (Barc); 2014 Feb; 50(2):113-20. PubMed ID: 24619588
[TBL] [Abstract][Full Text] [Related]
18. Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma.
Shiver MB; Mahmoud F; Gao L
N Engl J Med; 2015 Oct; 373(16):1580-2. PubMed ID: 26466009
[No Abstract] [Full Text] [Related]
19. Idelalisib: Targeting the PI3 Kinase Pathway in Non-Hodgkin Lymphoma.
Sujobert P; Rioufol C; Salles GA
Cancer J; 2016; 22(1):12-6. PubMed ID: 26841011
[TBL] [Abstract][Full Text] [Related]
20. Idelalisib approved for trio of blood cancers.
Cancer Discov; 2014 Oct; 4(10):OF6. PubMed ID: 25274697
[No Abstract] [Full Text] [Related]
[Next] [New Search]